Expanded trinucleotide repeats 1 cause many neurological diseases. These include Machado-Joseph disease (MJD) 2 and Huntington's disease (HD) 3 , which are caused by expanded CAG repeats within an allele of the ataxin-3 (ATXN3) and huntingtin (HTT) genes, respectively. Silencing expression of these genes is a promising therapeutic strategy, but indiscriminate inhibition of both the mutant and wild-type alleles may lead to toxicity, and allele-specific approaches have required polymorphisms that differ among individuals. We report that peptide nucleic acid and locked nucleic acid antisense oligomers that target CAG repeats can preferentially inhibit mutant ataxin-3 and HTT protein expression in cultured cells. Duplex RNAs were less selective than single-stranded oligomers. The activity of the peptide nucleic acids does not involve inhibition of transcription, and differences in mRNA secondary structure or the number of oligomer binding sites may be important. Antisense oligomers that discriminate between wild-type and mutant genes on the basis of repeat length may offer new options for developing treatments for MJD, HD and related hereditary diseases.
Expanded trinucleotide repeats have been implicated in at least 19 inherited diseases 1 , including MJD 2 and HD 3 . These diseases are autosomal dominant disorders with most patients expressing both mutant and wild-type alleles. Toxicity of the mutant protein is usually attributed to aggregation of the mutant protein or alteration of native protein-protein interactions. MJD, one of the most common ataxias with an incidence as high as 1 in 4,000 in some ethnicities 2 , remains incurable. It is usually first diagnosed in adults, with patients eventually becoming wheelchair bound or bedridden, and is caused by expanded CAG repeats repeats are normal, 445 repeats indicates disease) within the ATXN3 gene. HD has an incidence of 5-10 per 100,000 individuals in Europe and North America 3, 4 . Unaffected individuals have up to 35 repeats, whereas HD patients can have from 36 to 4100 repeats 5 . The disease is characterized by adult onset and progressive neurodegeneration. Like MJD, there is no cure. HD is caused by the expansion of CAG trinucleotide repeats within the first exon of the HTT gene, leading to disruption of protein function and neurodegeneration.
Antisense oligonucleotides 6 or double-stranded RNAs [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] have been proposed as a therapeutic alternative to small-molecule drugs, which cannot disrupt the many toxic interactions formed between proteins and mutant HTT or ataxin-3 (ref. 17) . Although small interfering (si)RNAs can inhibit HTT expression after infusion into the central nervous system 10 , most double-stranded or antisense oligonucleotides tested to date inhibit expression of the mutant and wild-type protein indiscriminately [6] [7] [8] [9] [10] . HTT is known to play an essential role in embryogenesis, neurogenesis and normal adult function 18, 19 , raising concerns that agents inhibiting both mutant and wild-type HTT may induce serious side effects in HD patients, especially if chronic administration is necessary. One approach to distinguish mutant from wild-type alleles in HD and other neurological diseases involves siRNAs that target single-nucleotide or deletion polymorphisms [11] [12] [13] [14] [15] [16] . But differences in polymorphisms between patients complicate routine clinical application of allele-specific RNA interference (RNAi).
To identify agents that block the neurodegenerative effects of the mutant gene while preserving the normal biological function of the wild-type allele, we tested whether single-stranded oligomers might discriminate between wild-type and mutant alleles based on differences in the lengths of the expanded mRNA sequences. Our rationale, based on the ability of triplet-repeat sequences within RNA to form hairpin structures ( Supplementary Fig. 1 online) 20 , was that because the structures formed by wild-type and mutant mRNAs possess different energies and stabilities, they might enable selective recognition of the mutant allele and subsequent selective inhibition of mutant protein expression. These differences are likely to be subtle, but even small differences may be enough to achieve useful levels of discrimination. Alternatively, the expanded repeats create additional target sequence and more potential binding sites. For example, an allele with a wild-type repeat number of 20 would accommodate a maximum of three 20-base oligomers, whereas a mutant allele with 40 repeats would be large enough to accommodate six 20-base oligomers.
To test this hypothesis, we synthesized 19-base peptide nucleic acid (PNA)-peptide conjugates targeting HTT mRNA (Supplementary Table 1 online and Fig. 1a ,b) and examined PNA-mediated inhibition of HTT expression in GM04281 patient-derived fibroblast cells (wild-type HTT allele contains 17 repeats and mutant HTT allele contains 69 repeats) ( Fig. 1c ). PNAs are a class of DNA/RNA mimics with an uncharged amide backbone that facilitates recognition of target sequences within RNA structure 21 . Unless otherwise noted, PNA conjugates were synthesized to contain a cationic peptide D-Lys 8 at the C terminus to promote the import of PNAs into cells 22 .
We targeted the CAG repeat region (REP19) and also the 5¢ junction (5J/HTT) and the 3¢ junction (3J/HTT) because complementarity to mRNA sequence outside the CAG repeat may further enhance the specificity for targeting mutant HTT mRNA relative to other cellular mRNAs. PNA conjugates REP19 (PNA REP19) and 3J/HTT (PNA 3J/ HTT) inhibited expression of HTT protein ( Fig. 1d ) and were chosen for further analysis. Inhibition of mutant HTT expression by PNA REP19 and PNA 3J/HTT was characterized by IC 50 values of 0.34 mM and 0.96 mM, respectively (Fig. 1e,f and Supplementary  Fig. 2 and Supplementary Table 2 online) and 3.5-fold and fivefold selectivities (wild-type IC 50 /mutant IC 50 ), respectively, 4 d after transfection. Inhibition decreased as we progressively adjusted the PNA target site downstream of that of HTT/3J, thereby gradually decreasing complementarity to the CAG repeat ( Supplementary  Fig. 3 online) . PNA REP19 selectively inhibited expression of mutant HTT relative to wild-type HTT for up to 22 d after a one-time addition to cells ( Fig. 1g ). Noncomplementary control PNAs CTL1 and -CTL2 did not inhibit HTT expression.
Many genes contain CAG repeats, including some that are essential for cellular function. At concentrations sufficient for selective inhibition of mutant HTT, addition of PNA REP19 did not affect expression of representative genes containing CAG repeats, including TATA box binding protein (TBP) (19 CAG repeats), ATN1 (15 CAG repeats), FOXP2 (40 consecutive glutamines encoded by mixed CAG and CAA codons), AAK1 (6 CAG repeats) and POU3F2 (6 CAG repeats) ( Fig. 1h and Supplementary Fig. 4a online) and did not cause cellular toxicity or affect rates of cell proliferation ( Supplementary Fig. 4b ).
Cells began to exhibit toxic effects when PNA REP19 was added at concentrations Z 2 mM, a concentration almost fourfold greater than that required for allele-selective inhibition ( Fig. 1i and Supplementary Fig. 4c ).
To test the consequences of selectively inhibiting expression of mutant HTT protein on phenotypes related to HD, we added PNA REP19 to primary neuronal cell medium spiny neurons (MSN) cultures derived from YAC128 transgenic mice ( Fig. 1j and Supplementary Fig. 5 online) 23, 24 . In this model, full-length human HTT mRNA containing 128 CAG repeats is expressed under control of its endogenous promoter in mice that also express wild-type murine HTT. MSN cells expressing mutant HTT protein are more susceptible to apoptosis upon addition of glutamate 24 . Addition of PNA REP19 to striatal cultures was neuroprotective against glutamate-induced toxicity, reducing the percentage of apoptotic YAC128 cells to B30%, similar to levels seen in wild-type MSN. Although not a perfect mimic of the situation in vivo because it is an engineered transgene model with mutant human HTT expression along with two wild-type mouse htt alleles, this experiment offers a first indication that the strategy may exert a protective effect in neuronal cells. The PNAs are complementary to both mRNA and chromosomal DNA and could, in theory, block transcription by binding to HTT DNA. It is known that the binding of PNAs to mRNA does not reduce mRNA levels 25 . By contrast, the binding of PNAs to DNA blocks transcription and reduces mRNA levels 26 . We observed that addition of PNA REP19 did not decrease levels of HTT mRNA (monitored by quantitative PCR) or alter levels of RNA polymerase 2 at the HTT promoter (monitored by chromatin immunoprecipitation) (Supplementary Fig. 6 and Supplementary Methods online). Indeed, efficient inhibition of both HTT alleles increased levels of HTT mRNA by a mechanism that does not involve enhancing the stability of HTT mRNA. These data are consistent with a mechanism of our alleleselective PNAs binding to mRNA and blocking translation rather than binding to DNA and inhibiting transcription.
Given the many options for improving the activity of antisense oligonucleotides through changing their lengths or introducing chemical modifications, we attempted to optimize allele-selective inhibition by varying PNA length and peptide conjugation. PNApeptide conjugates that were 16 and 13 bases in length (PNA REP16 and PNA REP13, respectively) were potent and selective inhibitors with IC 50 values of 0.39 mM and 0.47 mM, respectively ( Fig. 2a,b and Supplementary Fig. 2 ). PNA REP13 did not affect expression of other proteins when used at 1 mM ( Supplementary Fig. 7 online) . These results suggest that shorter PNAs can achieve potent and selective inhibition and broaden the options for designing effective agents.
A simple chemical modification to PNAs is replacement of D-arginine for D-lysine in the attached peptide. PNA REP19Arg was as potent an inhibitor (0.33 mM) as PNA REP19 attached to D-Lys 8 (0.34 mM), but selectivity for the mutant allele relative to the wild-type allele was reduced (1.9-fold for PNA REP19Arg versus 3.5-fold for PNA REP19) ( Fig. 2c, Supplementary Fig. 2 and Supplementary  Table 2 ). This demonstrates that the composition of the peptide sequence affects selectivity for inhibition of mutant versus wild-type protein. The importance of cationic peptide sequence for recognition is not surprising; we have previously documented examples where replacement of an attached peptide that contains lysine with an analogous peptide that contains arginine substantially alters recognition of complementary nucleic acids 27 .
Another straightforward modification is attachment of the peptide domain to the N rather than the C terminus of the PNA to afford PNA REP19N. In contrast to results showing lower selectivity with PNA REP19Arg relative to PNA REP19, PNA REP19N showed greater selectivity than PNA REP19. The IC 50 value for inhibiting mutant HTT expression was 2.1 mM, with relatively no obvious inhibition of wild-type HTT at concentrations as high as 16 mM ( Fig. 2d and Supplementary Fig. 2 ). This experiment demonstrates that improved selectivity can be achieved by varying conjugate design. We observed no inhibition of other proteins and only mild toxicity (Supplementary Fig. 7) .
In contrast to PNAs, which have a neutral amide backbone, oligonucleotides have negatively charged phosphodiester backbones. Because of this basic difference in their chemical properties relative to PNAs, oligonucleotides will have a much different potential for developing antisense oligomers for therapy. Oligonucleotides are approved drugs and are being used in several clinical trials, and this clinical experience may offer practical advantages for their development for treating HD.
To explore whether this difference in chemical properties might influence the capacity for allele-selective inhibition, we tested singlestranded oligonucleotides that contain locked nucleic acid (LNA) bases 28 . LNA is an RNA analog that contains a methylene bridge between the 2¢-O and 4¢-C of the ribose (Fig. 1a) . LNA bases can be placed at any position and allow the thermal stability of oligonucleotides to be precisely tailored for any application. In contrast to the neutral amide backbone of PNAs, LNAs have a negatively charged phosphodiester backbone, allowing us to use cationic lipid to introduce LNAs into cells. LNA oligomers are being tested in clinical trials 28 . We observed allele-selective inhibition of mutant HTTexpression by LNA/REP or LNA/3J (Fig. 2e,f and Supplementary Fig. 8a online) . Inhibition by LNA/REP and LNA/3J was characterized by IC 50 values of 0.017 and 0.086 mM, respectively ( Supplementary Fig. 2 and Supplementary Table 2 ). These IC 50 values are lower than those achieved using PNA-peptide conjugates, but because the transfection protocols differ, it is impossible to draw direct conclusions regarding relative potencies. Inhibition of wild-type HTT was r30% at 100 nM, the maximum concentration tested. Concentrations of LNA that selectively blocked expression of mutant HTT did not affect other genes that contain CAG repeats ( Supplementary Fig. 8b ). LNA/REP caused a modest decrease in levels of HTT mRNA relative to noncomplementary LNA controls ( Supplementary Fig. 8c ). In contrast to PNAs, LNAs that contain LNA bases spread throughout a DNA backbone form DNA:RNA hybrids upon binding to mRNA and can recruit RNase H 29 . The resultant cleavage may explain the observed lower levels of mRNA.
The potency and widespread use of duplex RNAs (siRNAs) 30 make them a good benchmark for evaluating the effectiveness of PNAs and LNAs. To test whether siRNAs would also achieve selective inhibition of mutant HTT, we introduced duplex RNAs analogous in sequence to PNA REP19, PNA 5J/HTT and PNA 3J/HTT into GM04281 fibroblast cells. Like LNAs, and unlike PNA-peptide conjugates, siRNAs have a phosphodiester backbone and we used cationic lipid to assist their entry into cells. We observed inhibition of HTT expression by siRNA/REP and siRNA/5J (Fig. 2g,h , Supplementary Fig. 2 ) characterized by IC 50 values of 0.005 and 0.018, respectively (Supplementary Table 2 ). siRNA/REP revealed a narrow window for selectivity with relatively low statistical significance (Fig. 2g) , whereas siRNA/5J exhibited a selectivity of approximately threefold ( Fig. 2h and Supplementary Table 2 ). Our RNAs were not chemically modified and duplex RNAs with well-chosen modifications might achieve better selectivity.
Most HD patients have mutant mRNAs with 40-50 CAG repeats 5 . We extended our studies to patient-derived fibroblast cell lines GM04869 (wild-type allele, 15 repeats; mutant allele, 47 repeats), GM04719 (wildtype allele, 15 repeats; mutant allele, 44 repeats) and GM04717 (wild-type allele, 20 repeats; mutant allele, 41 repeats) ( Fig. 3) . Upon addition of PNA REP19 to cells, we observed inhibition of mutant HTT in GM04869 (Fig. 3b) , GM04719 ( Fig. 3d) and GM04717 (Fig. 3f ) cells with selectivities (wild-type IC 50 value/mutant IC 50 value) of 2.1, 1.8 and 1.2, respectively (Supplementary Fig. 9 and Supplementary Table 2 online), values reduced relative to the 3.5-fold selectivity achieved in GM04281 cells (Fig. 1e) . We observed slight decreases in the potency of inhibition of mutant HTT as the number of mutant repeats was decreased from 47 to 44 and 41. The observation that the most potent inhibition of wild-type HTT occurred in the cell line (GM04717) with the most repeats in the wild-type allele is consistent with a correlation between the number of repeats and susceptibility to inhibition by PNA REP19. However, additional experiments are needed to better evaluate this hypothesis.
Because we had previously observed that attachment of the D-Lys 8 peptide to the PNA N terminus improves selectivity in GM04281 cells (Fig. 2d) , we tested N-linked conjugate PNA REP19N in the cell lines that possess mutant alleles with fewer CAG repeats. We observed inhibition of mutant HTT in GM04869 (Fig. 3c) , GM04719 ( Fig. 3e) and GM04717 (Fig. 3g ) cells with selectivities (wild-type IC 50 value/mutant IC 50 value) of 43.5, 41.8 and 41.5, respectively (Supplementary Fig. 9 and Supplementary Table 2 ). These data suggest that simple chemical modifications could potentially extend allele-selective inhibition of HTT protein expression to a broader subset of HD patients.
We selected ATXN3, the gene in which a CAG repeat expansion causes MJD 2 , as a target to test whether allele-selective inhibition could be achieved with other genes containing repeats. To examine the potential for allele-specific inhibition in MJD cells, we obtained patient-derived cell line GM06151, which is heterozygous for an expanded CAG repeat (wild-type allele, 24 repeats; mutant allele, 74 repeats). The 74 repeats of the mutant allele fall within the middle of the range of repeat numbers found in patient samples 31 . Wild-type HTT Figure 3 Selectivity is affected by the number of repeats in mutant HTT. All quantification of protein levels in fibroblast cells by western analysis is derived from at least three independent experiments. Examples of immunoblots used for quantification are shown in Supplementary Figure 9 . (a) Separation by SDS-PAGE of wild-type and mutant HTT protein variants in four different patient-derived cell lines. The first number is the number of repeats in the mutant allele, the second number is the number of repeats in the wild-type allele.
(b-g) Effect on HTT protein expression of adding REP19 to GM04869 cells (b), REP19N to GM04869 cells (c), REP19 to GM04719 cells (d), REP19N to GM04719 cells (e), REP19 to GM04717 cells (f) and REP19N to GM04717 cells (g).
We tested PNA conjugates that targeted the CAG repeat region (PNA REP19), the 5¢ junction (PNA 5J/ATX), and the 3¢ junction (PNA 3J/ATX) ( Fig. 4a, Supplementary Fig. 10 and Supplementary  Table 2 online). PNA REP19 selectively inhibited expression of mutant ataxin-3 with an IC 50 value of 0.36 mM (Fig. 4b) . Conjugates that target the 5¢ and 3¢ junctions also caused selective inhibition, with IC 50 values of 0.7 mM and 2.2 mM, respectively (Fig. 4c,d) . These data suggest that our strategy can be extended beyond HTT to other therapeutic targets. We also tested siRNA/REP. Similar to our observations for inhibition of HTT protein expression ( Fig. 2) , this siRNA was an inhibitor of ataxin-3 expression but yielded less-selective reduction of the mutant protein than did PNA REP19 (Fig. 4e) . A failure of a repeat-targeted siRNA to selectively inhibit ataxin-3 expression had been reported previously 11 .
One obstacle to therapy for HD or MJD will be delivery to the central nervous system because oligonucleotides are not distributed to the brain after intravenous or oral administration. Single-stranded oligonucleotides can be delivered directly to the central nervous system and block gene expression 32 . Although LNAs have not been used in animal models of HD or MJD, they have been administered into rodent brains by several methods (intrathecal, intracerebroventricular and intrastriatal) 33, 34 . Toxicity is minimal and potent inhibitory effects were observed for targeting deltorphin II 33 and miRNA-21 (ref. 34) .
Much attention has been focused on allele-selective inhibition using siRNAs complementary to sequences that have single-nucleotide or deletion polymorphisms [11] [12] [13] [14] [15] [16] . Although an advantage of this approach is that it involves familiar RNAi technology, the diversity of polymorphisms within patient populations would necessitate developing multiple siRNAs. Even then, this approach, based on single-nucleotide polymorphisms, is unlikely to benefit patients like the one from whom our benchmark patient-derived cell line GM04281, which has none of the most commonly identified polymorphisms 14 , was derived. We were able to perform experiments in GM09197 cells that have a deletion polymorphism and have been used to observe siRNA-mediated allele-selective inhibition 16 . LNA/REP offered better selectivity than the best allele-selective RNA (Supplementary Fig. 11 online) .
Patient populations are heterogeneous and approaches that target polymorphisms, triplet repeats or make no attempt at allele-selectivity may benefit different groups of patients. One advantage is that our approach uses one oligomer strand rather than the two needed for siRNAs, simplifying issues associated with clinical development such as compound synthesis and the potential for off-target effects. Conversely, although we demonstrate that optimizing the structure of the oligomer can lead to better selectivity over a wide range of repeats, it may be difficult, using our strategy, to achieve adequate selectivity for patients with shorter repeats.
Another important issue is the minimum efficacy sufficient for successful application in vivo. Complete inhibition of mutant protein expression might not be necessary to achieve beneficial therapeutic effects; even partial reduction of mutant protein levels may be adequate. Conversely, partial inhibition of wild-type protein may not have adverse consequences because the remaining wild-type protein may be sufficient for function. The window for therapy may be relatively broad, requiring less than complete inhibition of mutant protein expression and tolerating partial reduction in wild-type protein levels. Such information will help set the therapeutic window for drug development.
Given that the allele-selective inhibition of HTT and ataxin-3 occurs intracellularly, it is difficult to assign an exact molecular mechanism to the effects we have observed. Clearly, some complementarity to the CAG repeat is essential, because potency is lost when downstream regions are targeted ( Supplementary Fig. 3 ). Although the number of oligomers bound to the mutant and wild-type expanded repeats may contribute to selectivity, our evidence involving different PNAs, LNAs and siRNAs is consistent with a mechanism that at least partially involves an ability of PNAs and LNAs to sense structural differences between extended repeats in the cell. Addition of PNAs does not reduce levels of mRNA or recruitment of RNA polymerase 2 to the HTT promoter ( Supplementary Fig. 6 ), consistent with a steric blocking mechanism in which the PNA binds to mRNA rather than DNA. This 'steric blocking' mode of action for antisense PNAs was expected based on previous studies of PNAs complementary to mRNA 25 .
Our findings offer two lessons. The first is that single-stranded oligomers can discriminate among sequences inside cells on the basis of context-in this case the length of a polyglutamine tract and the potential of different repeat lengths to form energetically different structures-rather than base differences. The second is that the potential for developing single-stranded oligomers as alleleselective treatment for genetic disease is greater than had been appreciated previously. There is broad potential for optimizing the selectivity and potency of our most promising candidates. Antisense oligomers for other diseases are making good progress in clinical trials 35 and appear to offer near-term potential for wider therapeutic application. Exploiting the ability of antisense oligomers to selectively recognize mutant nucleic acid sequences offers a promising strategy for developing therapies for HD, MJD and other triplet-repeat disorders. 
METHODS
Cell culture and transfection. PNA-peptide conjugates were synthesized and purified as desccribed 22, 26 . LNA oligonucleotides were provided by Sigma-Aldrich. siRNAs were purchased from Integrated DNA Technologies (IDT). Patient-derived fibroblast cell lines GM04281, GM06151, GM04719, GM04869, GM04717, GM04795 and GM09197 were obtained from the Coriell Institute. Cells were maintained at 37 1C and 5% CO 2 in MEM (Sigma) supplemented with 10% heat inactivated FBS (Sigma) and 0.5% MEM nonessential amino acids (Sigma). Cells were plated in 6-well plates at 60,000 cells/well in supplemented MEM 2 d before transfection. Stock solutions of PNA-peptide conjugates were heated at 65 1C for 5 min before use to dissolve any aggregates that may have formed. PNA-peptide conjugates were diluted to the appropriate concentration using OptiMEM (Invitrogen) and then added to cells. After 24 h, the media containing PNA-peptides were removed and replaced by fresh supplemented MEM. Unless indicated otherwise, cells were harvested 4 d after transfection for protein assay. siRNAs or LNAs were transfected to cells using RNAiMAX (Invitrogen) according to the manufacturer's instructions. The appropriate amount of the lipid (3 ml for 100 nM oligonucleotides) was added to OptiMEM containing oligonucleotides and the oligonucleotide-lipid mixture (250 ml) was incubated for 20 min. OptiMEM was added to the mixture to a final volume of 1.25 ml and then added to cells. The media were exchanged 24 h later with fresh supplemented MEM.
Analysis of HTT and ataxin-3 expression. Cells were harvested with trypsin-EDTA solution (Invitrogen) and lysed. The protein concentration in each sample was quantified with bicinchoninic acid (BCA) assay (Thermo Scientific Figs. 12 and 13 online) . Gels were run at 70 V for 15 min followed by 100 V for 4 h. For separation of HTT variants containing shorter CAG repeats, gels were run at 70 V for 15 min, then 110 V for 6 h. The electrophoresis apparatus was placed in an ice-water bath to prevent overheating of the running buffer. We monitored expression of actin protein to ensure even loading on protein in each lane. In parallel with analysis for HTT expression, portions of each protein lysate sample were analyzed for b-actin expression by SDS-PAGE (7.5% acrylamide pre-cast gels; Bio-Rad). These gels were run at 70 V for 15 min followed by 100 V for 1 h. After gel electrophoresis, proteins were transferred to membrane (Hybond-C Extra; GE Healthcare Bio-Sciences). Ataxin-3 and b-actin were analyzed by SDS-PAGE (7.5% acrylamide pre-cast gels; Bio-Rad). Primary antibodies specific for each protein were obtained and used at the indicated dilution ratio: anti-HTT antibody (MAB2166; 1:10,000; Chemicon), anti-ataxin-3 antibody (MAB5360; 1:10,000; Chemicon), and anti-b-actin antibody (1:10,000; Sigma). HRP conjugate anti-mouse or anti-rabbit secondary antibody (1:10,000 and 1:5,000, respectively; Jackson ImmunoResearch Laboratories) was used for visualizing proteins using SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific). Protein bands were quantified using ImageJ software. The percentage of inhibition was calculated as a relative value to a control sample.
Neuronal cell glutamate susceptibility assay 23, 24 . YAC128 mice (FVBN/NJ background strain) were obtained from Jackson Labs. The male YAC128 mice were crossed to WT female FVBN/NJ mice and P1-P2 pups were collected and genotyped by PCR. The primary cultures of striatal MSN were established from YAC128 and control WT pups. Striata were dissected, diced and digested with trypsin. After dissociation, neurons were plated on poly-L-lysine (Sigma)coated 12-mm round coverslips (Assistent) in Neurobasal-A medium supplemented with 2% B27, 1 mM glutamine and penicillin-streptomycin (all from Invitrogen) and kept at 37 1C in a 5% CO 2 environment. PNA was added to the 9-days-in-vitro (DIV) MSN. The 13-DIV MSN were exposed for 7 h to 250 mM glutamate in Neurobasal-A added to the culture medium. Immediately after the treatment with glutamate, neurons were fixed for 30 min in 4% paraformaldehyde plus 4% sucrose in PBS (pH 7.4), permeabilized for 5 min in 0.25% Triton-X-100 and stained by using the DeadEnd fluorometric TUNEL System (Promega). Nuclei were counterstained with 5 mM propidium iodine (PI) (Molecular Probes). Coverslips were extensively washed with PBS and mounted in Mowiol 4-88 (Polysciences). For quantification six to eight randomly chosen microscopic fields, each containing 100-300 MSN, were counted for YAC128 and WT cultures. The number of TUNEL-positive neuronal nuclei was calculated as a fraction of PI-positive neuronal nuclei in each microscopic field. The fractions of TUNEL-positive nuclei determined for each microscopic field were averaged and the results are presented as means ± s.e.m. (n ¼ number of fields counted). MSN cells were supported in culture by surrounding glial cells, but only MSN cells were counted during the neuroprotection assay.
PNA REP19 was added at the concentration of 0.25 mM and 0.5 mM, 4 d before the glutamate application. Noncomplementary PNA -CTL1 was added at 0.5 mM. MSN were exposed to 250 mM glutamate at 13-DIV for 7 h, fixed, permeabilized and analyzed by TUNEL staining and PI counterstaining. The data are presented as mean ± s.e.m. (n ¼ 6-8 microscopic fields, 100-300 MSN per field).
For protein assays, after the addition of PNA REP19 at 9-DIV, the 13-DIV MSN were washed with ice-cold PBS and solubilized for 30 min at 4 1C in extraction buffer A (1% CHAPS, 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na 2 HPO 4 , 1.4 mM KH 2 PO 4 (pH 7.2), 5 mM EDTA, 5 mM EGTA and protease inhibitors). Extracts were clarified by centrifugation for 20 min at 10,000g at 4 1C and the upper solutions were collected for SDS-PAGE. For selectively harvesting MSN, cells were incubated with cell dissociation solution (Sigma) for 4 min at 37 1C and neuron basal-A medium with 10% FBS were added. MSN were detached from plate and most of the glial cells were not harvested. The combined solution was collected and lysed as previously described 23, 24 .
Caspase-3 activity assay. Caspase-3 activity was measured by hydrolysis of acetyl-Asp-Glu-Val-Asp p-nitroanilide (Ac-DEVD-pNA) according to the manufacturer's instruction in a colorimetric assay kit (Sigma). Fibroblast cells in 6-well plate were harvested as previously described. The cell pellet was resuspended in 15 ml of 1Â lysis buffer without protease inhibitor and incubated for 30 min on ice. Protein concentration was determined by BCA assay (Thermo Scientific). We mixed 50 mg of cell extract with 2 mM Ac-DEVD-pNA substrate to a total volume of 100 ml of 1Â assay buffer in a 96-well plate and incubated at 37 1C overnight. The absorbance was read at 405 nm.
Analysis of TBP, AAK1, ATN1, FOXP2 and POU3F2. The number of CAG repeats was estimated according to the published mRNA sequence in GenBank. TATA box binding protein (TBP) (B19 CAG repeats, NM_003194), AAK1 (6 CAG repeats, NM_014911), ATN1 (15 CAG repeats, NM_001940), FOXP2 (B40 CAAÁÁÁCAG repeats, NM_148899) and POU3F2 (B6 CAG repeats, NM_005604). Protein lysates were analyzed by SDS-PAGE (7.5% acrylamide pre-cast gels; Bio-Rad) followed by western blotting with anti-TBP antibody (1:2,000; Sigma), anti-AAK1 antibody (1:1,000; Abcam), anti-ATN1 antibody (1:300; Affinity Bioreagents), anti-FOXP2 antibody (1:1,000; Abcam) or anti-POU3F2 antibody (1:1,000; Abnova) ( Supplementary Fig. 13 ).
Statistical analysis and curve fitting. Student t-test was performed for evaluating statistical significance between two study groups. Each data plot from dose response experiments for inhibition of HTTor ataxin-3 was fit to the following model equation, y ¼ 100(1-x m /(n m +x m )), where y is percent inhibition of protein and x is concentration of synthetic oligomers. m and n are fitting parameters, where n is taken as the IC 50 value. 
